EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Change in Liver Function after Selective Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: JIVROSG-2001 PRESIDENT-ALBI – A Secondary Analysis of a Multicenter Randomized Controlled Trial

Yoshihisa Kodama, Masafumi Ikeda, Yasuaki Arai, Yoshitaka Inaba, Toshihiro Tanaka, Yasunori Arai, Shunsuke Sugawara, Hajime Yamazaki, Takeshi Aramaki, Hiroshi Anai, Shinichi Morita, Yasunari Fujinaga und 12 weitere

Liver Cancer · 05.12.2025 · 1-10

DOI: 10.1159/000549879 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Liver Cancer, online erschienen am 05.12.2025. Verfasst von Yoshihisa Kodama und 23 weiteren Autor:innen. Beteiligte Einrichtung: Center of Interventional Radiology, Keiyukai Sapporo Hospital, Sapporo, Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Liver function deterioration after transarterial chemoembolization (TACE) may preclude systemic therapy. The JIVROSG-1302 PRESIDENT study, a prospective, randomized controlled trial, showed a significantly higher local complete response rate with selective conventional TACE (cTACE) than with selective TACE using drug-eluting beads (DEB-TACE). However, this study did not assess the changes in liver function after selective TACE. The purpose of this study, JIVROSG-2001 PRESIDENT-ALBI, was to evaluate the change in liver function after selective TACE for unresectable hepatocellular carcinoma (HCC) using the same patient cohort.

Methods

The primary endpoint was ALBI grade deterioration rate after 3 months of TACE compared to DEB-TACE and cTACE. Secondary endpoints included the ALBI grade and score change and the identification of risk factors associated with liver function deterioration.

Results

A total of 197 patients with unresectable HCC were enrolled in this study. The ALBI grade deterioration rate at 3 months was 11% for the DEB-TACE group and 6% for the cTACE group, with no significant difference (p = 0.203). The mean ALBI score deterioration at 1 and 3 months was 0.06 and 0.02, respectively, and no notable deterioration in liver function was observed. The risk factors for ALBI score deterioration 1 month after selective TACE included large tumor diameter, high number of treated tumors, and treated vessels.

Conclusions

Selective TACE, whether DEB-TACE or cTACE, did not significantly impair the liver function. Even with selective TACE, larger tumors, multiple tumors, and a large number of treated blood vessels were associated with worsening liver function 1 month after TACE.

Schlagwörter

Stichwörter der Autor:innen

ALBI gradeHepatocellular carcinomaLiver functionLiver functional reserveTransarterial chemoembolization

Autor:innen und Institutionen

  • Center of Interventional Radiology, Keiyukai Sapporo Hospital, Sapporo, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Guest Researcher, National Cancer Center Hospital, Chūō, Japan.
  • Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Radiology, IVR Center, Nara Medical University, Kashihara, Japan.
  • Department of Diagnostic Radiology, National Cancer Center Hospital East, Kashiwa, Japan.

Zitieren

APA

Kodama, Y., Ikeda, M., Arai, Y., Inaba, Y., Tanaka, T., Arai, Y., Sugawara, S., Yamazaki, H., Aramaki, T., Anai, H., Morita, S., Fujinaga, Y., Seki, H., Sato, M., Kamimura, K., Ito, J., Tsurusaki, M., Nakazawa, T., Tokue, H., …, & Sone, M. (2025). Change in Liver Function after Selective Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: JIVROSG-2001 PRESIDENT-ALBI – A Secondary Analysis of a Multicenter Randomized Controlled Trial. Liver Cancer, 1-10. https://doi.org/10.1159/000549879

Vancouver

Kodama Y, Ikeda M, Arai Y, Inaba Y, Tanaka T, Arai Y, et al. Change in Liver Function after Selective Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: JIVROSG-2001 PRESIDENT-ALBI – A Secondary Analysis of a Multicenter Randomized Controlled Trial. Liver Cancer. 2025:1-10. doi:10.1159/000549879

BibTeX
@article{Kodama2025,
  author = {Kodama, Yoshihisa and Ikeda, Masafumi and Arai, Yasuaki and Inaba, Yoshitaka and Tanaka, Toshihiro and Arai, Yasunori and Sugawara, Shunsuke and Yamazaki, Hajime and Aramaki, Takeshi and Anai, Hiroshi and Morita, Shinichi and Fujinaga, Yasunari and Seki, Hiroshi and Sato, Mikio and Kamimura, Kenya and Ito, Junji and Tsurusaki, Masakatsu and Nakazawa, Tetsuro and Tokue, Hiroyuki and Abo, Daisuke and Kato, Kenichi and Hayashi, Natsuko and Sato, Osamu and Sone, Miyuki},
  title = {Change in Liver Function after Selective Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: JIVROSG-2001 PRESIDENT-ALBI – A Secondary Analysis of a Multicenter Randomized Controlled Trial},
  journal = {Liver Cancer},
  year = {2025},
  pages = {1--10},
  doi = {10.1159/000549879}
}
Kostenlos starten →